Home > Insider Trading > Filing (0001022079-24-000208)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1022079	Quest Diagnostics Inc	DGX	Services-Medical Laboratories (8071)	161387862

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1222679	E Michael Prevoznik	500 Plaza Drive Secaucus NJ 07094	Svp & General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-11-29	35,146	$86.63	73,624	No	4	M	Direct
Common Stock	Disposition	2024-11-29	3,009	$162.26	70,615	No	4	S	Direct
Common Stock	Disposition	2024-11-29	32,137	$163.15	38,478	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualifed Stock Option (right to buy)	Disposition	2024-11-29	35,146	$86.63	35,146	$86.63

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2029-02-18	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	5,618	Indirect	401(k)/SDCP

Footnotes

This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
This transaction was executed in multiple trades at prices ranging from $161.690 to $162.680. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $162.705 to $163.615. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.
The options vest in three equal annual installments beginning on the first annual anniversary of the grant date.